Rosiglitazone reduces the development and rupture of experimental aortic aneurysms.

@article{Jones2009RosiglitazoneRT,
  title={Rosiglitazone reduces the development and rupture of experimental aortic aneurysms.},
  author={Alun Jones and Rajdeep Deb and Evelyn Torsney and Franklyn A. Howe and Mathew Dunkley and Yanosha Gnaneswaran and David C. Gaze and Hosaam Nasr and Ian M. Loftus and Mathew Thompson and Gillian W. Cockerill},
  journal={Circulation},
  year={2009},
  volume={119 24},
  pages={3125-32}
}
BACKGROUND Development and rupture of aortic aneurysms involve a combination of complex biological processes. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, has been shown to have a broad spectrum of effects in vivo. The hypothesis that rosiglitazone would reduce aneurysm expansion or rupture was tested in the angiotensin II (Ang II)-induced hypercholesterolemic mouse model. METHODS AND RESULTS Apolipoprotein E-deficient mice, 12 months of age, were allocated to 4… CONTINUE READING